Telesis Bio logo

Telesis Bio(OTC) DNAY

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-5%
1 Month+1,000%
N/A
Telesis Bio last closing stock price
MetricPriceDate
Last closeUSD 0.012026-10-13
Telesis Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10,900%USD 0.002026-10-02
1 month+1,000%USD 0.002026-09-11
3 month+10%USD 0.012026-07-15
Year to date-78%USD 0.052025-12-31
1 year-4.76%USD 0.012025-10-13
3 year-99.93%USD 16.742023-10-13
5 year-99.99%USD 191.522021-10-14
Since inception-100%USD 333.002021-06-18

Telesis Bio Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.33M

Net Income (TTM)

-$40.08M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

DNAY News

3 strands of DNA

Why Codex DNA Trounced the Market Today

Eric VolkmanDec 29, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telesis Bio

Codex DNA, Inc. operates in the synthetic biology sector, focusing on the development, manufacturing, and sale of advanced instruments, reagents, and complementary services. The company primarily serves pharmaceutical firms and academic laboratories globally, while also catering to government institutions and contract research organizations.

Products and Services
  • BioXp system for transforming digital DNA sequences into synthetic DNA
  • BioXp portal for online DNA sequence design and assembly
  • Biofoundry Services for endpoint-ready BioXp products
Growth Outlook
  • Recent quarterly revenue of $1.57 million shows stability
  • Strong demand for synthetic biology solutions is expected to drive growth
  • Investment in R&D continues to enhance product offerings
Financial Highlights
  • Trailing twelve months revenue of $15.66 million reflects consistent performance
  • Gross profit margin improved to 64.43% in Q3 2024
  • Current ratio of 3.71 indicates strong liquidity position
Codex DNA, Inc. has established itself as a key player in the synthetic biology industry, leveraging innovative technologies to meet the needs of its diverse customer base. The BioXp system and associated services are designed to streamline the process of DNA synthesis, making it more accessible for researchers and organizations. The company's focus on research and development is expected to yield new products and enhancements, positioning it well for future growth. Financially, Codex DNA has shown resilience, with a recent quarterly revenue of $1.57 million, indicating a stable demand for its offerings. The gross profit margin has seen a notable improvement, reflecting effective cost management and operational efficiency. Additionally, a current ratio of 3.71 suggests that the company maintains a strong liquidity position, which is crucial for navigating the competitive landscape of the synthetic biology sector. Overall, Codex DNA, Inc. presents a compelling opportunity for investors interested in the evolving field of synthetic biology.
AI Generated • Sep 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

147

CEO

Todd R. Nelson, PhD, MBA

Website

telesisbio.com

Headquarters

San Diego, CA 92121-2993, US

DNAY Financials

Key Financial Metrics (TTM)

Gross Margin

61.62%

Operating Margin

-169.18%

Net Income Margin

-173.49%

Return on Equity

-125.42%

Return on Capital

-73.11%

Return on Assets

-67.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.90M

Operating Income

-$35.06M

EBITDA

-$28.57M

Operating Cash Flow

-$36.28M

Capital Expenditure

-$1.79M

Free Cash Flow

-$38.08M

Cash & ST Invst.

$4.51M

Total Debt

$16.29M

Telesis Bio Performance Analysis

Telesis Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 11,043,000N/A
20222022-12-31USD 27,435,000148.4%
20232023-12-31USD 27,509,0000.3%
Telesis Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3037.0%
Q32023-09-30-35.7%
Q22024-06-30N/A
Q32024-09-301.0%
Telesis Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -23.92N/A
20222022-12-31USD -29.6123.8%
20232023-12-31USD -29.56-0.2%
Telesis Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3024.3%
Q32023-09-30-32.1%
Q22024-06-30N/A
Q32024-09-3046.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$1.57M

-75.2%

Gross Profit

$1.01M

-71.3%

Gross Margin

64.43%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

212

N/A

Net Income

-$7.26M

+34.7%

EBITDA

$1.01M

+109.2%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$4.51M

-85.9%

Total Debt

$16.29M

-60.9%

Accounts Receivable

$1.26M

-78.4%

Inventory

$1.10M

-52.1%

Long Term Debt

$14.09M

-65.6%

Short Term Debt

$2.21M

+184.9%

Return on Assets

-67.78%

N/A

Return on Invested Capital

-74.79%

N/A

Free Cash Flow

-$4.54M

+70.1%

Operating Cash Flow

-$4.38M

+64.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RADRite Aid Corporation
$0.65-16.81%
ISOIsoPlexis Corporation
$0.76+0.00%
EYENEyenovia, Inc.
$7.56+3.99%
CERCCerecor Inc.
$2.93-1.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About DNAY

What is the current price of Telesis Bio?

Telesis Bio is trading at N/A per share.

What is the 52-week range for Telesis Bio?

Over the past 52 weeks, Telesis Bio has traded between N/A and N/A.

How much debt does Telesis Bio have?

As of the most recent reporting period, Telesis Bio reported total debt of $34.38M.

How much cash does Telesis Bio have on hand?

Telesis Bio reported $1.75M in cash and cash equivalents in its most recent financial results.

What is Telesis Bio’s dividend yield?

Telesis Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services